We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
12.2.2026 07:00:00 CET | Business Wire | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to different skin types, life stages, and aesthetic goals.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211375008/en/
Sculptra is the first proven regenerative biostimulator, backed by over 25 years of clinical use.2-6 With a unique poly-L-lactic acid (PLLA-SCA™) formulation, Sculptra re-engages the skin’s renewal process, stimulating collagen and elastin for healthy looking skin.3,7-11 Over the decades, it has evolved into a versatile treatment that delivers regenerative benefits across all three skin layers, helping to gradually restore volume, firmness, radiance and skin quality, and smoothing wrinkles and folds over time.2,3,7-14
“What excites me about this unique program is how it aims to capture the nuance of clinical practice: different protocols, different goals, and different outcomes, all unified by a science-first approach to aesthetic personalization. And beyond the science, we also notice an emotional journey – seeing patients regain confidence, feel more like themselves, and experience a deeper sense of wellbeing as their natural beauty is restored over time." MS. PRIYANKA CHADHA, FRCS (PLAST)
AMER CLINIC, LONDON |
Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients – who were all new to injectable aesthetics – over two years, offering a long-term view of how Sculptra performs over time.1 Its launch captures the patients’ personal reflections, results, and before & after treatment imagery, offering a powerful lens into both clinical outcomes and emotional impact.1
The campaign highlights the rich diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.1 Grounded in Galderma’s AART™ (Assessment, Anatomy, Range, and Treatment) methodologies and HIT™ (Holistic Individualised Treatment) protocols, it demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.1
Whether renewing natural volume, improving skin quality, or repositioning tissue for a lifted appearance, each case will highlight Sculptra’s adaptability across diverse indications and patient needs.1 As well its natural, long-lasting clinical outcomes, the campaign captures the emotional resonance of treatment, with improved confidence, self-recognition, and wellbeing seen throughout the group, while also leaving them with a positive first impression of aesthetic treatments.1
“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life. This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.” ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE CENTER FOR INNOVATION |
Learn more about We Are All Sculptrahere.
About Sculptra
Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide progressive and sustained regenerative effect across all three skin layers.2-6 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.2,15-18 Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.8-11 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.2,17,19,20
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
1. | Galderma. Data on file. We Are All Sculptra. 2025 | |
2. | U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed December 2025. | |
3. | Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042. | |
4. | Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6. 2024; Paris, France. | |
5. | Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791. | |
6. | Zubair R, et al. SPLASH: Split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg. 2024;50(12):1155-1162. doi: 10.1097/DSS.0000000000004417. | |
7. | Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France. | |
8. | Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States. | |
9. | Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States. | |
10. | Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229. | |
11. | Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51. | |
12. | Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010;62(3):448–62. doi: 10.1016/j.jaad.2009.07.040. | |
13. | Galderma. Data on File (MA-47133). | |
14. | Mu X, et al. 12-Month Effectiveness and Safety of PLLA Treatment of Midface in Chinese Subjects: A Multicenter, Randomized, No-Treatment Controlled Study. Presented at AMWC. March 30 to April 1, 2023. Monte-Carlo, Monaco. | |
15. | Zhang S and Duan E. Fighting against skin aging: the way from bench to bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755. | |
16. | Shuster S, Black MM, and McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-643. doi: 10.1111/j.1365-2133.1975.tb05113.x. | |
17. | Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–922. doi: 10.1111/dsu.12164. | |
18. | Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239. | |
19. | Hexsel D, Hexsel CL, and Cotofana S. Introducing the L-Lift: A Novel Approach To Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122-1124. doi: 10.1097/DSS.0000000000002015. | |
20. | Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC. March 30 - April 1, 2023. Monte-Carlo, Monaco. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260211375008/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press Release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press Release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press Release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 15:00:00 CEST | Press Release
Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partner and customer bases in key markets across Europe, Asia, and North America. A strategic global partnership spanning tech, fan engagement, brand marke
Kraken Launches Bitcoin Vault to Make Earning on Bitcoin Easy for Millions of Customers27.5.2026 15:00:00 CEST | Press Release
Kraken is launching Bitcoin Vault, a new product within Kraken Earn designed to help customers put their Bitcoin to work in a simple and trusted way. Built for long-term Bitcoin holders, Bitcoin Vault enables customers to earn BTC-denominated rewards while holding Bitcoin. Bitcoin Vault is powered by Veda, with strategy design and risk curation by Sentora. Their platforms are designed to manage risks and allocate the vaults to well-known onchain protocols like Aave, Morpho, Tydro and more. It is designed to make earning on Bitcoin more accessible, whether someone already holds Bitcoin with conviction or is just starting to build a long-term position. For many investors, Bitcoin is an asset they plan to hold forever and Bitcoin Vault is built around that behavior. Instead of introducing more complexity, Kraken offers a more intuitive path: hold Bitcoin, earn rewards in BTC and manage it directly from a Kraken account. “Many Bitcoin holders on Kraken have made it clear they want simple w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom